Publications by authors named "Areti Eleftheriadi"
Expert Opin Drug Saf
October 2024
Article Synopsis
- This safety analysis examines the occurrence of mucosal/cutaneous Candida infections in patients using ixekizumab (IXE) for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis.
- Data from 25 clinical studies indicated a low incidence rate of 1.2-2.0 per 100 patient-years, with most infections being mild, typically single occurrences, and largely resolved during the studies without requiring treatment discontinuation.
- Overall, the findings suggest that the risk of Candida infections with IXE is low and usually mild-to-moderate in severity, with effective management strategies in place.
